NephroGenex (NRX) Reports IDSMB Recommendation to Continue Oral Pyridorin Phase 3 as Planned
Tweet Send to a Friend
NephroGenex, Inc. (Nasdaq: NRX) announced that the independent Data and Safety Monitoring Board (DSMB) for the Company’s pivotal Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
